翻译和验证苏黎世慢性中耳量表(ZCMEI-21)的英语,以提供一种英语工具来评估慢性中耳炎(COM)与健康相关的生活质量。
试点翻译研究,包括认知汇报,前瞻性多中心横断面心理测量验证研究。
在三个不同的英语国家(英国,美国和澳大利亚)。
患有COM的成年患者。
ZCMEI-21(ZCMEI-21-E)的英文翻译和EQ-5D问卷的五级版本。EQ-5D,这构成了健康相关生活质量的通用衡量标准,由描述性系统评分和视觉模拟量表组成。统计结果包括单项目描述性统计,内部一致性(Cronbach'sα)作为可靠性指标,以及结构效度。
共纳入124例COM患者。平均年龄为50.1岁(SD16.9岁),男性72人(58.1%)。ZCMEI-21-E的Cronbach'sα为0.91,表明具有优异的内部稠度。ZCMEI-21-E总分与EQ-5D描述性系统得分的收敛结构效度的Spearman相关系数为0.55(P<0.0001),与EQ-5D视觉模拟量表为0.57(P<0.0001)。
ZCMEI-21-E是一个新的经过验证的问卷,为临床医生提供了一个简短的,全面可靠的工具来量化患有COM的患者与健康相关的生活质量。ZCMEI-21-E可用于临床常规以及结果研究和监测。
To translate and validate the Zurich Chronic Middle Ear Inventory (ZCMEI-21) for the English language in order to provide an English instrument to assess health-related quality of life in chronic otitis media (COM).
Pilot translation study including cognitive debriefings, prospective multicentre cross-sectional psychometric validation study.
Four tertiary referral centres in three different English-speaking countries (UK, USA and Australia).
Adult patients suffering from COM.
The English translation of the ZCMEI-21 (ZCMEI-21-E) and the five-level version of the EQ-5D questionnaire. The EQ-5D, which constitutes a generic measure of health-related quality of life, consists of a descriptive system score and a visual analogue scale. Statistical outcomes included single-item descriptive statistics, internal consistency (Cronbach\'s α) as an indicator of reliability, as well as construct validity.
A total of 124 patients suffering from COM were included. The mean age was 50.1 years (SD 16.9 years), and 72 (58.1%) were males. The Cronbach\'s α of the ZCMEI-21-E was 0.91, suggesting an excellent internal consistency. The Spearman\'s correlation coefficient of the ZCMEI-21-E total score was 0.55 (P < 0.0001) for convergent construct validity with EQ-5D descriptive system score and 0.57 (P < 0.0001) with the EQ-5D visual analogue scale.
The ZCMEI-21-E is a new validated questionnaire that provides clinicians with a short, comprehensive and reliable instrument to quantify health-related quality of life in patients suffering from COM. The ZCMEI-21-E may be of use in clinical routine as well as in outcome research and monitoring.